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Abstract, The number and affinity of glucocorticoid binding sites in peripheral mononuclear leukocytes of patients 
with atopic dermatitis (AD) and healthy controls were determined under baseline conditions and after a defined oral 
glucocorticoid treatment. Patients with A D (n = 15) exhibited significantly more glucocorticoid receptors (GR) per cell 
than the control group (n = 22), while the G R affinity did not differ. Methylprednisolone treatment resulted in a signif-
icant reduction of the G R sites per cell in the steroid-treated control group (n = 10) in contrast to the patients. The dis-
sociation constant was not affected by methylprednisolone treatment in either group. In view of the therapeutic effi-
ciency of glucocorticoids in A D and findings of abnormal c A M P and cAMP-phosphodiesterase activity, the elevated 
G R concentrations in A D lend support to the hypothesis of a compensatory G R upregulation due to an insufficient 
action of endogenous Cortisol or to altered cAMP-induced G R expression. 
Introduction 
Studies on patients with atopic dermatitis (AD) have 
revealed a variety of immunological, hormonal and psy-
chological [1,2] derangements including elevations of IgE 
levels [3, 4], disordered cell-mediated immunity [5-7], 
abnormal c A M P and cAMP-phosphodiesterase activity 
[8, 9] and an impairment of p-adrenoceptor function [10, 
11]. Recent investigations pointed to a possible hormonal 
dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) system in A D . Slightly lowered baseline values of 
Cortisol [12] in face of a normal adrenomedullar function 
[13], minor imbalances in the circadian rhythm of Cortisol 
serum levels [14] as well as a reduced urine excretion rate 
of steroid metabolites contrasting with normal Cortisol 
blood levels [15] have been noted. 
Topical and systemic administration of glucocorticoids 
is of major importance in the treatment of A D . The 
effects of glucocorticoids are mainly mediated via specific 
intracellular receptors which have been identified in vari-
ous mammalian and human tissues, e.g. the skin [16-18], 
lung [19], brain [20] and mononuclear leukocytes [21-23]. 
As the glucocorticoid receptor (GR) has been shown 
to underlie an autoregulatory control in skin fibroblasts 
[17, 18] and in human leukocytes [21-26], the present 
study was designed to explore the potential role of G R 
autoregulation for the alteration of the H P A system in 
A D . 
Material and Methods 
Subjects 
Fifteen inpatients (3 men and 12 women) suffering from A D and 22 
healthy controls (11 men, 11 women) without personal history of asth-
ma, hay fever or A D participated in the study voluntari ly with informed 
consent. The patients were aged between 18 and 36 years ( m e a n ± S D : 
23.4 ± 5.6) and the controls for baseline studies between 19 and 42 years 
( m e a n ± S D : 28.5 ± 6 . 3 ) . Ten of the healthy subjects (4 men, 6 women; 
mean age ± S D : 24.3 ± 2.8 years), who had the same age as the patients, 
agreed to further participate in the study and received the same steroid 
dosage as the patients for the autoregulation study. 
A l l participants were withdrawn from any systemic therapy with 
corticoids or adrenocorticotropic hormone at least 2 months prior to the 
study. M e d i c a t i o n , if any, with (3-blocking and/or sleep-inducing drugs 
was stopped 3 or more days before entering the study. Cutaneous 
lesions of A D were treated only with corticoid-free ointments at least 
1 week before onset and during the study. 
Exc lus ion cri ter ia were prevalence of severe internal illness and 
alcohol, drug or nicotine abuse. Seven of the patients and 4 of the 10 
healthy controls were taking birth control pills. 
The diagnosis of A D was based on the history of recurrent flexura! 
eczema, personal and/or family history of atopy and clinical criteria of 
A D as established by Hani f in and Rajka [27]. The severity of cutaneous 
involvement was evaluated according to Costa ct a l . [28] and revealed 
moderate to marked disease activity. The score ranged between 37 and 
69points ( m e a n ± S D : 4 7 . 6 ± 10.6) before therapy and between 11 and 
55 points ( m e a n ± S D : 27.9+10.7) at the end of the study. None of the 
patients suffered from actual bronchial asthma. 
Study Design 
Af te r obtaining the baseline G R and hormone parameters, all 
patients and the steroid-treated controls underwent a 1-mg dcxametha-
sone suppression test ( D S T ) and subsequent oral methylprednisolone 
therapy as shown in table 1. The D S T was used to evaluate the integrity 
of the feedback regulation of the H P A system. 
F o r determinat ion of G R binding characteristics and hormone data 
peripheral venous b lood samples were collected into E D T A - c o n t a i n -
ing plastic tubes (Sarstedt, F R G ) . 
Cell Preparation and Binding Assay 
Mononuc lea r cel l fraction was prepared by sodium metrizoate-
F ico l l (Sigma, St. L o u i s , M o . , U S A ) density gradient cent! if ligation 
[29]. Ce l l s were washed twice in phosphate-buffered saline ( P B S , p i I 
7.4; Boehr inger , M a n n h e i m , F R G ) for 10 min , incubated for 60 min at 
37 °C in P B S and then washed again to allow sufficient dissociation of 
endogenous hormone. The final concentration of cells was determined 
using a Coul te r counter ( M o d e l S5, Coul ter Electronics L t d . U K ) . V i a -
bili ty of cells exceeded 9 5 % , as judged from their ability to exclude try-
pan blue. Contaminat ion by erythrocytes was < 10%, by granulocytes 
and monocytes < 8 % . 
B i n d i n g experiments as described by Rupprecht et al . [25] were 
carried out at 37 °C in plastic microti ter plates in a total volume of 0.25 
m l . The displacing compound in a final concentration of 10 \iM unla-
beled dexamethasone (Sigma, St. Lou i s , M o . . U S A ) solved in 5% ctha-
no l , containing 5 m M D-glucose, was added to half of the samples to 
determine nonspecific binding immediately prior to the addition of 
[ 3 H]dexamethasone ( A m e r s h a m , U K ) . Increasing concentrations of 
[ 3 H]dexamethasone (specific activity: 84 Ci /mmol) from 1 to 40 nA/ 
were used. Saturation experiments were carried out at equil ibrium 
after 90 min incubation in P B S with 5 vaM D-glucose at 37 C . After 
incubation, bound ligand was separated from free ligand by rapid filtra-
tion through Scatron filters ( N o . 11731) with a Titertek cell harvester 
by two 5-second washes with P B S at room temperature. The filters 
were transferred into plastic vials , 5 ml of a toluene-based scintillation 
cocktail was added (Rotiszint 22: Ro th . Karlsruhe. F R G ) and they 
were monitored for tri t ium in a Beckman L S 1801 counter at about 54% 
efficiency. A l l samples were assayed in triplicate with a variation coef-
ficient < 7 % . 
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F i g . 1. Seatehard plot of | \ I |dexamethasone binding to human 
mononuclear leukocytes. Specifically bound/free ( ( H|dexamethasone 
is plotted versus specifically hound f H )dexamethasone. 
Table 1. Study design 
Day Time C J1 ucoeoriicoid doses 
1 7 a.m. 
4 p .m. 
11 p.m. 1 mg dexamethasone 
2 7 a.m. 
4 p.m. 
3--6 7a .m. 8 mg methylprednisolone 
7 -S 7a .m. 4 mg methylprednisolone 
8 4p .m. 
Table 2. Cortisol mean 4 S D values ( 
controls (n 10) 
A B 
7 a ,m. 4 p . m . 7 a 
B lood samples 
hormone data 
hormone -f receptor data 
hormone data 
hormone data 
hormone -f receptor data 
C 
4 p . m . 4 p . m . 
Patients 27.5 + 13.8 13.4 + 11.3 1.6 + 1.4 4.1 + 4.0 5.6 ± h.9 
Controls 25.1 t 8.6 14.6 + 6.9 2.3 + 1.5 3.3 + 3.3 7.7 i 5.7 
A Baseline levels. K after oral administration of 1 mg dexame-
thasone: C after oral methylprednisolone treatment. 
Table 3. G R sites in female patients and female controls taking and 
not taking birth control pills under baseline conditions and after methyl-
prednisolone treatment 
Patients 
Baseline 
Prednisolone 
Controls 
Baseline 
Prednisolone 
Pill 
n - 7 
3.783 + 1.658 
3.353 +. 1.105 
n - 4 
2.642 * 567 
2.030 + 470 
N o pill 
n - 5 
3.886+ 1.537 
3.250 ± 1.643 
n - 2 
2.764 + 85<> 
2.087+ 14 
5,000 -I 
Baseline Corticoid treatment 
F i g . 2. G R sites per ce l l . M e a n s ± S E , i n patients wi th A D ( • , 
n = 15), the cort icoid-treated controls ( H , n = 10) and the whole cont ro l 
group ( • , n = 22) before (baseline) and after g lucocor t icoid treatment. 
The asterisks indicate significant differences ( p < 0 . 0 2 ) . 
Baseline Corticoid treatment 
F i g . 3. K d . M e a n s ± S E , in patients wi th A D ( • . n = 15), the cor t i -
coid-treated controls ( ^ , n = 10) and the whole control group ( • , 
n —22) before (baseline) and after g lucocor t icoid treatment. 
Recep tor levels and the dissociat ion constant ( K d ) were de te rmined 
by Scatchard plots [30]. A typica l Scatchard plot of [ 3 H]dexamethasone 
is shown i n figure 1. 
Specif ic b ind ing was de termined by subtracting the nonspecific 
f rom total b ind ing . Nonspeci f ic b ind ing ( in percent o f total b inding) at a 
concentra t ion of 10 nM [ 3 H]dexamethasone was 28 ± 18% in patients 
and 26 ± 15% i n controls . 
Cortisol Assay 
C o r t i s o l was measured by an enzyme- l inked immunoassay ( E l i a s , 
F r e i b u r g , F R G ) . T h e lower detect ion l imi t was 22 nmol/1, and the in t ra-
and interassay coefficients of var ia t ion were 6% for both . 
C o r t i s o l nonsuppress ion was defined as the inabi l i ty to suppress 
both postdexamethasone Cortisol levels to below 5 ug/dl [31]. 
Statistical Analysis 
Pre l imina ry estimates o f b ind ing parameters f rom saturat ion 
experiments were p rov ided by the E B D A program. F i n a l estimates of 
b ind ing parameters were de te rmined wi th a compute r ized nonl inear , 
least-square regression analysis [32]. T h i s weighted curve fi t t ing pro-
gram assumes b ind ing according to the law of mass act ion to indepen-
dent classes o f b ind ing sites. T h e results are expressed as the mean 
± S D , and as the m e a n ± S E in the figures. 
D a t a were analyzed using the t-test for pa i red or group samples and 
Pearson's product moment cor re la t ion . A l l significance levels are two-
ta i led . 
Results 
Cortisol mean values of the patients and the controls 
did not differ significantly at any of the blood sampling 
time points during the 1-mg DST (table 2). Three of the 
patients and 2 of the controls fulfilled the criterion for Cor-
tisol nonsuppression. 
Comparison of the postmethylprednisolone Cortisol 
levels to the 4 p.m. baseline levels revealed significant 
reduction in patients and controls (p<0.03). 
The patients had significantly (p<0.02) more G R sites 
per cell than controls (fig. 2). After methylprednisolone 
therapy the patients revealed a slightly smaller mean 
number of G R sites per cell in relation to the baseline val-
ues (mean baseline: 3,894± 1,521; after treatment: 
3,394± 1,189, not significant), whereas in the controls 
(n= 10) a significant reduction of the G R sites was found 
(mean baseline: 2,695 ±582; after treatment: 2,036 ±410 , 
p<0.02). 
The significantly more G R binding sites per cell per-
sisted after therapy in the patient group when compared 
with the steroid-treated control group (p<0.002). 
There was no difference in baseline or methylpredniso-
lone-treated G R sites between female subjects taking 
birth control pills and those who did not (table 3). 
The K d did not differ at baseline condition and after 
methylprednisolone treatment in both groups (fig. 3). No 
relations were found between age, sex, Cortisol levels, 
severity of the skin disorder and G R binding parameters 
under the conditions studied. 
Discussion 
Although slightly lowered baseline Cortisol serum con-
centrations in patients with A D have been observed [12], 
our study is in accordance with reports on normal Cortisol 
levels in A D [15]. Twenty percent of the patients with A D 
and 20% of the controls showed no suppression of Cortisol 
to below 5 [xg/dl after 1 mg dexamethasone. However, 
abnormal DST data may not only occur in various dis-
eases but can also be induced by multiple interference fac-
tors such as stress and weight loss in healthy subjects [33, 
34]. Therefore, the abnormal DST results obtained in A D 
and healthy controls may represent an unspecific finding. 
As no data are available on G R binding characteristics 
in A D we used peripheral blood mononuclear leukocytes 
to study G R pharmacology, partly for their easy accessi-
bility but also for their relevance to the pathogenesis in 
A D [35] as emphasized by the finding that bone marrow 
transplantation for other reasons could either confer the 
state of atopy to former nonatopics [36, 37] or may clear 
A D in patients with a concomitant immune deficiency 
disorder [38]. 
The elevated G R concentrations found in the patients 
with A D are probably not representing a causal factor, 
otherwise worsening of the skin lesions would be expected 
at the beginning of glucocorticoid treatment due to an 
increased number of activated hormone-receptor com-
plexes. A n upregulation of the glucocorticoid binding 
sites as a compensatory mechanism is more likely. Possi-
ble hypotheses for such an upregulation may be altera-
tions in cAMP-induced G R expression [39], activation of 
the G R synthesis by unspecific mediators [40] or a relative 
biological inefficiency of endogenous corticoids. The lat-
ter hypothesis might be supported by the well-known ben-
efit of glucocorticoids for the treatment of A D and also by 
the frequent occurrence of a rebound phenomenon after 
discontinuation of glucocorticoid administration. A n 
increase in receptor protein half-life [39, 41] due to 
reduced cortisol-receptor interactions as supposed after 
depletion of endogenous Cortisol following metyrapone 
administration [26] or adrenalectomy [42], or an 
enhanced transcription rate for the G R [43] may also be 
responsible for the elevated G R sites in A D . 
No correlations were found between endogenous Cor-
tisol levels and G R binding sites in the control and patient 
group. This result is in accordance with previous studies in 
healthy and asthmatic subjects [26, 44, 45] and indicates 
that the plasma concentrations of endogenous glucocorti-
coids at the time of the G R assay are of minor importance 
for the estimation of G R number. 
However, prolonged glucocorticoid administration 
results in downregulation of the number of G R [18, 21, 
24] by influencing G R gene transcription [46] without sig-
nificantly affecting the binding affinity. In the controls 
methylprednisolone administration was followed by a sig-
nificant decrease in G R binding, whereas in the patients 
with A D only a slight reduction of G R binding was 
observed. This finding might be interpreted as a dimin-
ished downregulation of G R by exogenous glucocorti-
coids which could be due to the heterogeneity of the 
patient group shown by the greater standard deviation 
and might also be compatible with the hypothesis of a 
cAMP-induced overdrive of G R expression [39] or a rela-
tive biological inefficiency of endogenous Cortisol which 
would require a greater amount of exogenous glucocorti-
coids to downregulate the G R . However, it cannot be 
excluded that an eventual displacement of receptor-
bound methylprednisolone by dexamethasone during the 
assay may underlie different kinetics in patients with A D 
which might affect the estimation of K d and B m a x values. 
The use of monoclonal antibodies for quantification of 
G R expression [47] might overcome the difficulties with 
ligand exchange assays and furnish a direct proof for the 
hypothesis of a decreased G R downregulation in A D . 
As no data are available on G R in other inflammatory 
skin diseases so far, the specificity of the present findings 
is still questionable. However, although A D and bron-
chial asthma are often closely associated [48] and gluco-
corticoid therapy is efficient in both diseases [44], normal 
lymphocyte G R content and affinity has been described in 
asthmatic subjects [44, 45]. 
In line with observations that patients with A D exhibit 
a minor derangement of the H P A system shown by imbal-
ances of the circadian rhythm of Cortisol [14] and may have 
a reduced excretion of glucocorticoids [15], the here re-
ported alterations in G R binding characteristics on mono-
nuclear leukocytes lend further support to the view of A D 
as being a systemic rather than a mere cutaneous disease. 
Future perspectives might be the concomitant analysis 
of G R behavior in mononuclear leukocytes and cells of 
both involved and uninvolved skin areas of patients with 
A D . 
Acknowledgements 
W e thank M i s s Nis te lweck for excellent technical assistance. The 
Johannes and F r i eda M a r o h n Stiftung of the Un ive r s i t y of E r l angen -
Nurnbe rg p rov ided f inancial support . 
References 
1 Fauls t ich M E , W i l l i a m s o n D A , D u c h m a n n E G , C o n e r l y S L , 
Bran t l ey P P : Psychophysiological analysis o f atopic dermati t is . 
J Psychosom Res 1985;29:415-417. 
2 W h i t l o c k F A : Psychophysiologische A s p e k t e bei H a u t k r a n k h e i -
ten: A top i sche Dermat i t i s ; i n Bosse K , H i i n e c k e P (eds): Bei t rage 
zur Derma to log ie . E r l a n g e n , P e r i m e d , 1980, vo l 6, pp 141-159. 
3 W u t h r i c h B : Serum I g E in atopic dermati t is . C l i n A l l e r g y 1978; 
8:241-248. 
4 J u h l i n L , Johansson S G O , B e n n i c h H , H o g m a n C , Thyresson N : 
Immung lobu l in E in dermatoses. A r c h D e r m a t o l 1969;100:12-16. 
5 L o b i t z W C , H o n e y m a n J F , W i n k l e r N W : Suppressed ce l l -medi -
ated immuni ty in two adults wi th atopic dermati t is . B r J D e r m a t o l 
1972;86:317-328. 
6 Ro la -P leszczynsk i M , B l a n c h a r d R : A b n o r m a l suppressor ce l l 
function in atopic dermati t is . J Invest D e r m a t o l 1981;76:279-283. 
7 Schopf E , K a p p A , K i m C W : T-ce l l function i n atopic dermati t is -
C o n t r o l l e d examinat ion of concanaval in A dose-response relations 
i n cul tured lymphocytes . A r c h D e r m a t o l R e s 1978;262:37-44. 
8 Schwarz W , B o c k G , Horns t e in O P : P lasma levels of cycl ic nucleo-
tides are elevated i n atopic eczema. A r c h D e r m a t o l Res 1987;279: 
S59-S62. 
9 H o l d e n C A , C h a n S C , H a n i f i n J M : M o n o c y t e loca l iza t ion o f ele-
vated cycl ic A M P phosphodiesterase activity i n atopic dermati t is . 
J Invest D e r m a t o l 1986;87:372-376. 
10 Szent ivanyi A , H e l m O , S c h u l t z e P , S z e n t i v a n y i J : A d r e n o r e c e p t o r 
b ind ing studies wi th 3 -H-(d ihydroa lpreno lo l ) and 3-H-(d ihydroer -
gocryptine) o n membranes of lymphocytes f rom patients wi th 
atopic disease. A c t a D e r m V e n e r e o l (Stockh) 1980;92:19-21. 
11 Szent ivanyi A : The beta adrenergic theory of the atopic abnormal -
ity i n b ronchia l asthma. J A l l e r g y 1968;42:203-232. 
12 van de K e r k h o f P C M : P lasma aldosterone and Cortisol levels in pso-
riasis and atopic dermati t is . B r J D e r m a t o l 1981;106:423-428. 
13 A r c h e r C B , D a l t o n N , T u r n e r C , M a c D o n a l d D M : Invest igat ion of 
adrenomedul lary function in atopic dermati t is . B r J D e r m a t o l 
1987;116:793-800. 
14 H e u b e c k B , Schonberger A , Horns t e in O P : S ind Versch iebungen 
des z i rkad ianen Cor t i so l rhy thmus e in endokrines S y m p t o m des 
endogenen E k z e m s ? Hautarz t 1988;39:12-17. 
15 B u h l e s N , H o l z e l C , Spi te l ler G , H o l z m a n n H , A l t m e y e r P : D i s o r -
ders of s teroid metabol i sm in inf lammatory dermatoses. Z H a u t k r 
1987;62:1356-1363. 
16 Smi th K , Shuster S: Character isa t ion of the g lucocor t ico id receptor 
in human epidermis and dermis. C l i n E x p Derma to l 1987;12:83-88. 
17 B e r k o v i t z G D , Car te r K M , M i g e o n C J , B r o w n T R : D o w n r e g u l a -
t ion of the g lucocor t icoid receptor by dexamethasone in cul tured 
human sk in fibroblasts: Implicat ions for the regulat ion of a roma-
tase activi ty. J C l i n E n d o c r i n o l M e t a b 1988;66:1029-1036. 
18 O i k a r i n e n A , O i k a r i n e n H , M e e k e r C A , T a n E M L , U i t t o J : G l u c o -
cor t i co id receptors i n human sk in fibroblasts: Ev idence for down-
regulat ion of receptor by glucocor t icoid hormone . A c t a D e r m 
V e n e r e o l (Stockh) 1987;67:461-468. 
19 B a l l a r d P L , B a l l a r d R A : Cy top la smic receptors for glucocort icoids 
i n lung of the human fetus and neonate. J C l i n Invest 1974;53: 
477-486. 
20 F u x e K , W i k s t r o m A C , O k r e t S, A g n a t i L F , Har fs t rand A , Y u Z Y , 
G r a n h o l L , Z o l i M , V a l e W , Gustafsson J A : M a p p i n g of g lucocor t i -
c o i d receptor immunoreac t ive neurons i n the rat tel- and d ien-
cephalon using a monoc lona l ant ibody against the rat l iver gluco-
cor t i co id receptor . E n d o c r i n o l o g y 1985;117:1803-1812. 
21 Sh ipman G F , B l o o m f i e l d C D , Ga j l -Pecza l ska K , M u n c k A U , 
S m i t h K A : Glucocor t i co ids and lymphocytes . I I I . Effects of gluco-
cor t i co id adminis t ra t ion on lymphocyte g lucocor t icoid receptors. 
B l o o d 1983;61:1086-1090. 
22 L i p p m a n M , B a r r R : G l u c o c o r t i c o i d receptors i n pur i f ied subpop-
ulat ions of h u m a n per iphera l b l o o d lymphocytes . J I m m u n o l 1977; 
118:1977-1981. 
23 B r e n t a n i M M , Wajchenberg B L , Cesar F P , M a r t i n s V R : Regu l a -
t ion of the g lucocor t ico id receptor by glucocor t icoids in human 
mononuclear leucocytes. H o r m Res 1986;24:9-17. 
24 Schlechte J A , G i n s b e r g B H , Sherman B M : R e g u l a t i o n of the g lu-
cocor t ico id receptor in human lymphocytes . J S tero id B i o c h e m 
1982;16:69-74. 
25 Rupprech t R , K o r n h u b e r J , W o d a r z N , G o b e l C , Lugaue r J , Sinz-
ger C , B e c k m a n n H , R iede re r P , M i i l l e r O A : A u t o r e g u l a t i o n of the 
g lucocor t ico id receptor in man : Up- regu la t i on by metyrapone is 
avo ided by dexamethasone pretreatment . J N e u r o e n d o c r i n o l 1990; 
2:803-806. 
26 Rupprech t R , K o r n h u b e r J , W o d a r z N , Lugaue r J , G o b e l C , H a a c k 
D , M u l l e r O A , R i ede re r P , B e c k m a n n H : D i s t u r b e d g lucocor t ico id 
receptor autoregulat ion and cor t ico t ropin response to dexametha-
sone in depressives pretreated wi th metyrapone . B i o l Psychia t ry , 
in press. 
27 H a n i f i n J M , R a j k a G : Diagnos t ic features o f a topic dermati t is . 
A c t a D e r m V e n e r e o l Suppl (Stockh) 1980;92:44-47. 
28 Cos ta C , R i l l i e t A , Nico le t M , Saurat J H : Scor ing atopic dermati t is : 
T h e s impler the better? A c t a D e r m V e n e r e o l (Stockh) 1989;69: 
41-45 . 
29 B o y u m A : Separat ion of leukocytes f rom b l o o d and bone mar row. 
Scand J C l i n L a b Invest 1968;21:97-107. 
30 Scatchard G : The attraction of proteins for smal l molecules and 
ions. A n n N Y A c a d Sci 1949;51:660-672. 
31 C a r r o l l B J , M a r t i n F I , D a v i s B M : Resistance to suppression by 
dexamethasone of p lasma 1 1 - O H C S levels in severe depressive i l l -
ness. B r M e d J 1968;i i i :285-287. 
32 M c P e r s h o n G A : A pract ical computer-based approach to the anal-
ysis of rad io l igand b ind ing exper iments . C o m p u t Programs B i o -
m e d 1983;17:107-114. 
33 Berge r M , P i r k e K M , D o e r r P , K r i e g J C , Ze r s sen D : T h e l imi t ed 
ut i l i ty of the dexamethasone suppression test for the diagnostic pro-
cess in psychiatry. B r J Psychiatry 1984;145:372-382. 
34 Rupprecht R . Lesch K P : Psychoneuroendocr ine research in 
depression. I. H o r m o n e levels of different neuroendocr ine axes 
and the dexamethasone suppression test. J N e u r a l T r a n s m 1989; 
75:167-178. 
35 A r c h e r C B : C y c l i c nucleotide metabol i sm in a topic dermati t is . C l i n 
E x p D e r m a t o l 1987;12:424-431. 
36 Saar inen U M : Transfer o f latent atopy by bone mar row transplan-
tat ion? J C l i n A l l e r g y I m m u n o l 1984;74:196-200. 
37 T u c k e r J , Barne t son R , E d e n O B : A t o p y after bone ma r row trans-
planta t ion . B r M e d J 1985;290:116-117. 
38 Saurat J H : E c z e m a in p r imary immune deficiencies. C l u e to the 
pathogenesis o f atopic dermati t is wi th special reference to the W i s -
k o t t - A l d r i c h syndrome. A c t a D e r m V e n e r e o l Supp l (Stockh) 1985; 
114:125-128. 
39 D o n g Y , A r o n s s o n J A , O k r e t S: The mechan ism of c A M P - i n d u c e d 
g lucocor t ico id receptor express ion. J B i o l C h e m 1989;23: 
13679-13683. 
40 D a m o n M , R a b i e n M , Louba t i e re J , B l o t m a n F , Crastes de Paulet 
A : G l u c o c o r t i c o i d receptors i n fibroblasts f rom synovia l tissue. 
Changes dur ing the inf lammatory process. P r e l i m i n a r y results. 
Agen t s A c t i o n s 1986;17:478-483. 
41 Dis te lhos t C W : Recent insight into the structure and function of the 
g lucocor t ico id receptor . J L a b C l i n M e d 1989;113:404-412. 
42 T u r n e r B B : Tissue differentiat ion in the up-regula t ion of glucocor-
t ico id-b inding proteins in the rat. E n d o c r i n o l o g y 1986;118: 
1211-1216. 
43 Gus ta f s sonJ , Car l s t ed t -Duke J , Poel l inger L , O k r e t S, W i k s t o m A , 
B r o n n e g a r d M , G i l l n e r M , D o n g Y , Fuxe K , C i n t r a A , Harfs t rand 
A , A g n a t i L : B iochemis t ry , molecular b io logy, and physiology of 
the g lucocor t ico id receptor. E n d o c r Reviews 1987;8:185-234. 
44 T s a i B S , Wat t G , Koensnad i K , Townley R G . Lymphocy te gluco-
cor t ico id receptors i n asthmatic and control subjects. C l i n A l l e r g y 
1984;14:363-371. 
45 G r i e s e M , Kusenbach G , Lusebr ing K , Kos te r W , R o t h B , 
Re inhard t D : G l u c o c o r t i c o i d receptors in mononuclear b lood 
cells and their corre la t ion to endogenous and exogenous cort i -
coids in healthy and asthmatic chi ldren . E u r J Pediatr 1988;147: 
490-495. 
46 Rosewicz S, M c D o n a l d A R , M a d d u x B A , Goldf ine I D , Mies fe ld 
R L , L o g s d o n C D : M e c h a n i s m of glucocort icoid receptor down-
regulat ion by glucocort icoids . J B i o l C h e m 1988;263:2581-2584. 
47 A n t a k l y T , R a q u i d a n D , O ' D o n n e l l O , K a t n i c k L : Regu la t ion of 
glucocort icoid receptor expression. I. U s e of a specific r ad io immu-
noassay and ant iserum to a synthetic o f the N- t e rmina l domain . 
Endoc r ino logy 1990;126:1821-1828. 
48 A a s K : C o m m o n immunochemis t ry i n atopic dermati t is and bron-
chia l asthma. A c t a D e r m V e n e r e o l Supp l (Stockh) 1980;92:64-66. 
Rece ived : October 15, 1990 
A c c e p t e d : January 18, 1991 
M o n i k a Rupprecht , M D 
Depar tment of De rma to logy 
Hartmannstrasse 14 
D - W - 8 5 2 0 Er l angen ( F R G ) 
